Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05938270 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate the Biological Effects of Saruparib (AZD5305), Darolutamide, and in Combination in Men With Newly Diagnosed Prostate Cancer.
A Phase 1 study of Prostate Cancer, sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 120
- Enrollment target
- 19
- Study locations
NCT05938270: Recruiting Phase 1 study of Prostate Cancer, sponsored by AstraZeneca.
NCT05938270 is a Phase 1 study of Prostate Cancer that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 120 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (80% lower). The trial reports 19 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05938270, a Phase 1 study of Prostate Cancer, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 120 participants
- Enrollment target
- 19
- Study locations
Study Summary
A Study to Investigate the Biological Effects of Saruparib (AZD5305) Alone, Darolutamide Alone, and in Combination Given Prior to Radical Prostatectomy in Men with Newly Diagnosed Prostate Cancer (ASCERTAIN).
Primary Outcome
To assess the effects of study treatment on γH2AX change in participants with localised prostate cancer
Conditions Studied
Interventions
- DRUG Saruparib (AZD5305)
- DRUG Darolutamide
- OTHER No Treatment
Study Locations (19)
Other
- Research Site - Melbourne
- Research Site - South Brisbane
- Research Site - Amsterdam
- Research Site - Nijmegen
- Research Site - Barcelona
- Research Site - Barcelona
- Research Site - Madrid
- Research Site - Valencia
- Research Site - Ankara
- Research Site - Ankara
- Research Site - Istanbul
- Research Site - Cambridge
- Research Site - Manchester
- Research Site - Newcastle upon Tyne
Michigan
- Research Site - Detroit
Rhode Island
- Research Site - Providence
British Columbia
- Research Site - Vancouver
Ontario
- Research Site - Toronto
Quebec
- Research Site - Québec
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2023-09-21 |
| Est. Completion | 2026-08-17 |
| Phase | Phase 1 |
What NCT05938270 shows while recruiting
NCT05938270 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (80% lower).
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 3 interventions - of which Saruparib (AZD5305) is the first listed.
NCT05938270 lists 19 locations in 6 states (Other, Michigan, Rhode Island).
Frequently Asked Questions
What is clinical trial NCT05938270 about?
NCT05938270 is a clinical study titled "A Study to Investigate the Biological Effects of Saruparib (AZD5305), Darolutamide, and in Combination in Men With Newly Diagnosed Prostate Cancer.". A Study to Investigate the Biological Effects of Saruparib (AZD5305) Alone, Darolutamide Alone, and in Combination Given Prior to Radical Prostatectomy in Men with Newly Diagnosed Prostate Cancer (ASCERTAIN).
What is the current status of trial NCT05938270?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 120 participants. The study started on 2023-09-21. Estimated completion is 2026-08-17.
What conditions does trial NCT05938270 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT05938270?
The interventions under investigation include: Saruparib (AZD5305) (DRUG), Darolutamide (DRUG), No Treatment (OTHER).
Who is sponsoring clinical trial NCT05938270?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05938270 being conducted?
This trial has 19 study locations across Michigan, Rhode Island, British Columbia, Ontario, Quebec. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05938270's enrollment target sits among peer trials
120 301st of 735 higher than 427 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
RECRUITING · Phase 1
-
Study of STM-416p Administered to Patients Undergoing Radical Prostatectomy
RECRUITING · Phase 1
-
A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI